

Pfizer's Growing Strength in Oncology

Monday, May 28, 2007 - 10:11pm

[\(BUSINESS WIRE\)](#)--At next week's American Society of Clinical Oncology Meeting, Pfizer will present new information that underscores the depth and breadth of its oncology portfolio and the significant potential of projects advancing through the company's research and development pipeline.

Note: Details about key Pfizer presentations at ASCO are in the accompanying press release.

Pfizer's R&D pipeline in oncology is robust, with active programs in immunotherapy, signal transduction inhibition, and angiogenesis inhibition.

-- During the past 5 years, the number of R&D oncology projects in Pfizer has

In 2006, Pfizer's currently marketed products -- including Camptosar, Aromasin, Sutent -- accounted for approximately \$1.9 billion in revenues, an increase of 18 percent in one year.

Pfizer Inc Ray Kerins, 212-733-9203